Early Stage Drug Development Company

We’re a high value-added company that applies photoisomerization conversion technology

Shareholders

Shareholders information

  • Shareholder No. Rate Remark
    Byong-Cheol Shin 1,613,326 72.66% CEO
    KNU Technology Holdings 367,794 16.56% -
    Minority Shareholders 239,364 10.78% -
    Total 2,220,484 100%

    As of December 31, 2021

    Shareholder No. Rate Remark
    Byong-Cheol Shin 1,613,326 72.66% CEO
    KNU Technology Holdings 367,794 16.56% -
    Minority Shareholders 239,364 10.78% -
    Total 2,220,484 100%

    As of December 31, 2021